Celldex Therapeutics, Inc. (CLDX)

Market Cap	2.43B
Revenue (ttm)	6.88M
Net Income (ttm)	-141.43M
Shares Out	64.42M
EPS (ttm)	-2.92
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	418,705
Open	38.91
Previous Close	38.85
Day's Range	37.62 - 39.67
52-Week Range	22.11 - 53.18
Beta	1.56
Analysts	Strong Buy
Price Target	66.00 (+74.74%)
Earnings Date	May 2, 2024

About CLDX

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The c...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 10, 2008
• Employees: 160
• Stock Exchange: NASDAQ
• Ticker Symbol: CLDX

Financial Performance

In 2023, CLDX's revenue was $6.88 million, an increase of 192.02% compared to the previous year's $2.36 million. Losses were -$141.43 million, 25.9% more than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for CLDX stock is "Strong Buy." The 12-month stock price forecast is $66.0, which is an increase of 74.74% from the latest price.

Price Target

$66.0

(74.74% upside)

Analyst Consensus: Strong Buy